tbuckley/cabot-search huggingface dataset:
Endothelial Protein C Receptor (EPCR), Oxide Nitric Synthase (NOS) and Tissue Factor (Factor III) Gene Expression: The Role Like Promising Biomarkers In Sickle Cell Anemia
Authors: Bruno A. V. Cerqueira, Wendell Vilas Boas, Teresa Cristina Fonseca, Regiana Q. Souza, Milena Magalhães Aleluia, Bruna A. Cunha, Felipe A. Pimenta, Thassila Nogueira Pitanga, João Oliveira Reis, Sanzio Silva Santana, Marilda Souza Goncalves
Journal: Blood (2013)
AB0815 Intraarticular Triamcinolone plus Mepivacaine Provides A Rapid and Sustained Relief for Acute Gouty Arthritis
Authors: M. Andrés, A. Begazo, F. Sivera, P. Vela, E. Pascual
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout attacks are often considered as especially painful. Effective treatments for gout attacks - colchicine, NSAIDs, systemic or intra-articular corticosteroids, IL-1 blockers -result in a rapid subsidence of the attacks, but it usually requires 1–3 days (1–3) to relieve the symptoms. Our standard procedure in clinics is to add 2% mepivacaine to intra-articular triamcinolone, as we have repeatedly observed a very rapid and persistent subsidence of pain. Here we aimed to document this outcome in a prospective way. <h3>Methods</h3> Consecutive patients with crystal-proven gout and an acute, monoarticular attack were recruited. All cases were treated with an intra-articular injection of triamcinolone plus 2% mepivacaine, according to our clinical practice. Joint pain was registered using a 0–4 Likert semiquantitative scale (0=absent; 4=severe) at baseline and 15min, 6h, 24h, and 72h after the injection. Presence of joint swelling and erythema was also collected at baseline and after 72h. Treatment response after 72h was evaluated by both the physician and the patient on a 0–4 Likert scale (0=no effect; 4=complete resolution). Between-after comparisons were analyzed using Wilcoxon signed-rank test. <h3>Results</h3> A total of 24 patients were recruited, median (±SD) aged 64.8 years (±12.7), 22 males. Involved joints were 16 first metatarsophalangeal (1MTP), 5 knees, 2 wrists, and one ankle. Triamcinolone doses ranged from 10mg (1MTP) to 20–40mg (others). Median (p25–75) pain at baseline was 3 (2–3.8), joint swelling was present in all cases, and in 13 cases (54.2%) erythema was observed. After the intra-articular injection, a significant pain reduction was observed at all time-points, even at 15min after the injection, as shown in the Figure. No symptoms rebounds between time-points were reported. Treatment was effective as assessed by both patients and rheumatologists (3 (3–4) and 3.5 (3–4), respectively). <h3>Conclusions</h3> This small study confirms a rapid relief of gout attacks with adding mepivacaine to intra-articular corticosteroids, with a significant response even at 15min after the injection. Large, controlled studies should confirm these results. <h3>References</h3> Cochrane Database Syst Rev. 2014;9:CD010120. Arthritis Rheum. 2010;62:1060. Ann Rheum Dis. 2012;71:1839. <h3>Disclosure of Interest</h3> M. Andrés Speakers bureau: Menarini, A. Begazo: None declared, F. Sivera: None declared, P. Vela: None declared, E. Pascual: None declared
Re-Establishment and Characterization of an Extinct Line of Sheep with a Spontaneous Bleeding Disorder That Closely Recapitulates Human Hemophilia A.
Authors: Graça Almeida-Porada, Jyoti Desai, Charles Long, Mark Westhusin, Vladimir Pliska, Gerald Stranzinger, Hannes Joerg, David Thain, Hudson Glimp, Duane Kraemer, Christopher D. Porada
Journal: Blood (2007)
THU0629 The Cost-Effectiveness of Golimumab as An Add-on To Conventional Care Compared To CC for The Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland
Authors: R.H. Borse, E. McCann, O. McGill, C. Black, S. Kachroo, R. Insinga
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Golimumab (Gol) has been approved by the Scottish Medicines Consortium in the treatment of adults with severe active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence, who have had an inadequate response to or are intolerant to nonsteroidal anti-inflammatory drugs. <h3>Objectives</h3> To evaluate the cost-effectiveness (CE) of Golimumab (Gol) in addition to conventional care (CC) in the treatment of nr-axSpA, in Scotland, from an NHS perspective. <h3>Methods</h3> We built a Markov model to assess CE in nr-axSpA patients over their lifetimes. Among the treated population, disease progression through 60 weeks was based on the GO-AHEAD trial. Post-week 60, BASDAI/BASFI scores were held constant until week 260, when assumed the disease deterioration rate to be 50% of CC. At week 12, patients were responders if they had a ≥50% improvement from baseline BASDAI scores, otherwise they discontinued. We applied a fixed discontinuation rate, post-week 12. Patients reached equivalent health states to those on CC 24 weeks, post-discontinuation. Utilities were linked to BASDAI/BASFI scores based on trial data. We used a published equation using BASFI scores to estimate long term health care costs. Discounting was applied at 3.5%/year. Uncertainty was explored through sensitivity analyses. <h3>Results</h3> The average baseline values for age, BASFI and BASDAI scores (based on GO-AHEAD data) was 31 years, 5.01 and 6.49, respectively. Gol when added to CC, led to an increase of 2.06 QALYs (8.98 vs. 6.92) per patient at an additional net cost of £39,770 (£146,908 vs. £107,138) compared with CC alone. Gol resulted in an incremental cost-effectiveness ratio (ICER) of £19,280/QALY. The ICER was sensitive to the correlation between BASDAI/BASFI and health-care costs and utilities in sensitivity analyses. <h3>Conclusions</h3> Gol+CC is cost-effective compared with CC alone for the treatment of nr-axSpA in Scotland. <h3>Disclosure of Interest</h3> R. Borse Employee of: Merck &amp; Co., Inc, E. McCann Employee of: Merck &amp; Co., Inc, O. McGill Employee of: Merck &amp; Co., Inc, C. Black Employee of: Merck &amp; Co., Inc, S. Kachroo Employee of: Merck &amp; Co., Inc, R. Insinga Employee of: Merck &amp; Co., Inc
Vaccination with Lymphoma and Dendritic Cell Hybrids Intended as an Adjuvant Therapy for Lymphoma Patients - A Feasibility Study.
Authors: Sergiusz Markowicz, Anna Jakubowska-Mucka, Marzena Biernacka, Grzegorz Rymkiewicz, Anna Borawska, Irena Federowicz, Danuta Rozewska, Maria Sawadro-Rochowska, Hanna Polowniak-Pracka, Michal Szymczyk, Henryk Skurzak, Zygmunt Pojda, Jan Walewski
Journal: Blood (2006)
Euthanasia or Assisted Suicide in Patients With Psychiatric Illness
Authors: Martina A. Hodel, Manuel Trachsel
Journal: JAMA (2016)

To the Editor Drs Olié and Courtet1 commented on the report by Dr Kim and colleagues2 on euthanasia or assisted suicide (EAS) of psychiatric patients in the Netherlands, highlighting the challenges surrounding the legalization of EAS in patients with a psychiatric illness.
AB0824 Synovial Fluid Analysis in A Rheumatology Department. Past and Present
Authors: P. Cuevas, S. Rodriguez, J. Inciarte, P. Peris, A. Monegal, N. Guañabens
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> For decades the Departments of Rheumatology have used synovial fluid analysis for the differential diagnosis of various arthropathies, especially microcrystalline diseases. However, it is possible that access to new diagnostic techniques and new treatments has changed the frequency and characteristics of synovial fluid analysis. <h3>Objectives</h3> To compare the frequency and findings in synovial fluid analyses in two periods 10 years apart. <h3>Methods</h3> Retrospective cross-sectional study evaluating the synovial fluid analysis reports from a Rheumatology Department (including outpatient, inpatient and emergency departments) carried out for a 4-year period (2012- 2015). The results were compared with those obtained in a previous study conducted between 1998–2005. <h3>Results</h3> During the last 4 years we have analyzed a total of 440 samples of synovial fluid, with an average of 110±24.8 samples per year (range: 135–78), while in the previous study (1998–2005) 1,881 synovial fluid samples were analyzed, with an average of 235±54.8 samples per year (range: 326–162), decreasing the number of fluid analysis evaluations by 53%. In 31.8% of the current samples and in 18.8% of samples of the previous study microcrystals were detected. The identification of monosodium urate crystals (MSU) were observed in 50% and 49.1% of the current vs. the previous analysis of the samples, respectively, whereas calcium pyrophosphate dihydrate crystals (CPPD) were present in 44.2% and 47.4%, respectively. The identification of both crystals in the same sample (UMS + CPPD) was reported in 6% and 1% of the analyses in the current and previous study, respectively. In both studies, MSU crystals were more frequent in males (83% vs. 89% in the current and previous study), whereas in women CPPD crystals were observed in 48% and 64% of current and previous analyses, respectively. <h3>Conclusions</h3> In recent years a decrease in the number of synovial fluid analysis is observed. Although the proportion of synovial fluid analyses from pathologies other than crystal-induced arthritis has decreased, the proportion of detectable UMS and CPPD crystals has not changed. <h3>References</h3> Frecuencia y tipo de microcristales en el análisis del líquido sinovial. Experiencia a largo plazo en un Servicio de Reumatología. M.A. Martínez, R. Reyes, C. Moll, F.J. Rodríguez, P. GόmezRoyo, P. Peris y N. Guañabens Hospital Clínic. Universidad de Barcelona. Reumatología Clinica. 2006;2 (Espec Congr):11–180. <h3>Disclosure of Interest</h3> None declared
Granulocyte Colony-Stimulating Factor Inhibits CXCR4/SDF-1 Signaling and Overcomes Stromal-Mediated Drug Resistance in Acute Myeloid Leukemia Via Mir-146a
Authors: Hua Zhong, Lan Xu, Xin Li, Xian-fu Sheng, Fang-yuan Chen, Jiong Hu
Journal: Blood (2015)
Rescue of Erythropoietin-Deficient Mice From Anemia by Complementation with BAC Transgene.
Authors: Shun Yamazaki, Norio Suzuki, Naoshi Obara, Xiaoqing Pan, Ikuo Hirano, Kou-ichi Jishage, Kurisu Honda, Naoko Minegishi, Masayuki Yamamoto
Journal: Blood (2009)
Early Response to Therapy Is Significantly Associated with Genetic Subtype of Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group.
Authors: Mignon L. Loh, Elizabeth Raetz, Meenakshi Devidas, Stephen B. Linda, Michael J. Borowitz, Andrew J. Carroll, I.-Ming L. Chen, Julie M. Gastier-Foster, Nyla A. Heerema, Richard C. Harvey, Eric Larsen, Kelly Maloney, Cheryl L. Willman, Naomi Winick, Brent Wood, Stephen P. Hunger, William L. Carroll
Journal: Blood (2007)
Studies with Diluted Plasma Reveal the Presence of a Remarkably Potent Factor That Enhances the Motility of Cancer Cells and Is Quentched by Fibrinogen - a Novel View of Cancer Metastasis
Authors: Gabriela Schneider, Karol Serwin, Ewa Bryndza, Magdalena Kucia, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2012)
Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study
Authors: Michael Martin, Suphak Vanichseni, Pravan Suntharasamai, Udomsak Sangkum, Philip A Mock, Benjamaporn Chaipung, Dararat Worrajittanon, Manoj Leethochawalit, Sithisat Chiamwongpaet, Somyot Kittimunkong, Roman J Gvetadze, Janet M McNicholl, Lynn A Paxton, Marcel E Curlin, Timothy H Holtz, Taraz Samandari, Kachit Choopanya
Journal: The Lancet HIV (2016)
PTH-112 Association between Helicobacter Pylori Infection and Nonalcoholic Fatty Liver Disease in The United States
Authors: SJ Kang, D Kim
Journal: Gut (2016)

<h3>Introduction</h3> <i>Helicobacter pylori</i> infection has been implicated in the pathogenesis of various gastrointestinal, hematologic, and systemic diseases. Association between <i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease (NAFLD) is poorly characterised. The aim of this study was to investigate the association between <i>H. pylori</i> positivity with <i>cagA</i> status and NAFLD in the large general population. <h3>Methods</h3> The Third National Health and Nutrition Examination Survey (NHANES) from 1988 to 1994 was utilised in this study. NAFLD was defined by ultrasonographic detection of hepatic steatosis without other known liver diseases. Antibodies to <i>H. pylori</i> and <i>cagA</i> of participants 20 years and older were measured in using ELISA. <h3>Results</h3> Among total of 5,404 participants who had results of both ultrasonography and <i>H. pylori</i> serology, the prevalence of NAFLD was 31.9%. The prevalence of NAFLD was higher in <i>H. pylori</i> positive subjects (33.5±1.79%) than in negative subjects (26.1±1.65%, <i>p</i> &lt; 0.001). Compared with <i>cagA</i> positive group, participants with negative <i>cagA</i> had higher prevalence of NAFLD (31.1±2.30% vs. 36.4±2.37%, <i>p</i> &lt; 0.001). Overall participants with NAFLD had higher prevalence of <i>H. pylori</i> positivity in multivariable analysis (Odds ratio [OR]: 1.17; 95% confidence interval [CI]: 0.95–1.43) with marginal significance. With regard to presence of <i>cagA</i> protein, <i>H. pylori </i>and<i> cagA</i> positivity was not associated with NAFLD (OR: 1.05; 95% CI: 0.81–1.37) but, <i>cagA</i> negative <i>H. pylori</i> positivity was significantly associated with NAFLD in multivariable analysis (OR: 1.30; 95% CI: 1.01–1.67). <h3>Conclusion</h3> The prevalence of NAFLD was higher in <i>H. pylori</i> positive subjects than in negative subjects. Especially, <i>cagA</i> negative <i>H. pylori</i> positivity was significantly associated with NAFLD, independent of other known factors in the general population. <h3>References</h3> 1 Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. <i>Clin Liver Dis</i> 2007;<b>11</b>:1–16, vii. 2 Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. <i>Hepatology</i> 2013;<b>57</b>:1357–65. 3 Chung GE, Kim D, Kim W, <i>et al</i>. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. <i>J Hepatol</i> 2012;<b>57</b>:150–6. <h3>Disclosure of Interest</h3> None Declared
Comparative Analysis of Clinical Outcomes between Unrelated Donor Peripheral Blood Stem Cell Transplantation and Bone Marrow Transplantation for Leukemia.
Authors: Zhiping Fan, Qifa Liu, Kai Yang, Jing Sun, Dan Xu, Yu Zhang, Yong-qiang Wei, Chang-xiong Ye, Qianli Jiang, Fan-yi Meng
Journal: Blood (2006)
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
Authors: Josef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, Jeffrey R Curtis, Stephen Hall, Boulos Haraoui, Ronald van Vollenhoven, Christopher Cioffi, Cécile Ecoffet, Leon Gervitz, Lucian Ionescu, Luke Peterson, Roy Fleischmann
Journal: The Lancet (2016)
THU0525 Counting Synovial Fluid Monosodium Urate Crystals May Be Useful in The Management of Patients with Gout
Authors: P. Montagna, R. Brizzolara, C. Ferrone, S. Soldano, M. Cutolo, M.A. Cimmino
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is the most common form of arthritis, and its prevalence is increasing. The mainstay of its diagnosis is the identification of monosodium urate (MSU) crystals in the synovial fluid (SF) (1,2). In a recent study we tested a feasible and reliable technique for counting MSU crystals in the SF (3). This method could provide useful information for the management of patients with gout. <h3>Objectives</h3> To investigate correlations between MSU crystals count in SF and clinical characteristics of gout patients. <h3>Methods</h3> Forty-four consecutive patients (6 women) affected by gout diagnosed according to the ACR preliminary criteria were studied. Their SFs were examined: for crystal count, 20 ml of fresh SF were placed on a microscope slide and examined by compensated polarized microscopy (400x). The slide was divided into 4 equal parts drawing a cross with a pencil. Crystal count was obtained by continued viewing and in each quadrant the crystals were counted up to a maximum of 400 (maximum number of crystals/patient was 1600). Clinical information included: acute inflammation at the time of SF aspiration, disease duration, number of attacks, number of affected joints, presence of radiographic erosions, presence of tophi, chronic renal failure, type of antiinflammatory and urate lowering treatment (ULT), ESR, CRP, creatinine and serum uric acid (SUA). In five patients, crystal count was repeated after ULT. <h3>Results</h3> Mean age was 65.5±11.7 yrs and median disease duration was 6 years (range 0.1–35 years). Aspirated joints were the knee (40 SFs), elbow (1 SF), 1st metatarsophalangeal joint (2 SFs), and ankle (1 SF). Median crystal count was 273 (range 3–1600). Joints with recent (&lt;1 week) inflammation tended to have a higher SF crystal count than the asymptomatic ones (491 [range 3–1600] vs. 100 [range 4–1600]; p=0.1). The number of crystals in the SF correlated with SUA (p=0.04), but not with ESR and CRP. No correlations were found with clinical features. In the 5 patients on ULT, mean MSU crystals count decreased from 871 to 473 (p=0.05). <h3>Conclusions</h3> SF MSU crystals count is not associated with the clinical features of gout, correlates with SUA, and decreases with ULT. <h3>References</h3> Doherty M. Rheumatology 2009; 48:ii2-ii8. Pascual E et al. Current Opinion in Rheumatology 2011; 23:161–69. Montagna P et al. Reumatismo 2015; 67(1):29–32 <h3>Disclosure of Interest</h3> None declared
Plaque Composition in the Proximal Superficial Femoral Artery and Peripheral Artery Disease Events
Authors: Mary M. McDermott, Christopher M. Kramer, Lu Tian, James Carr, Jack M. Guralnik, Tamar Polonsky, Timothy Carroll, Melina Kibbe, Michael H. Criqui, Luigi Ferrucci, Lihui Zhao, Daniel S. Hippe, John Wilkins, Dongxiang Xu, Yihua Liao, Walter McCarthy, Chun Yuan
Journal: JACC. Cardiovascular imaging (2016)
Assessment and Monitoring of Constitutional Symptoms in Patients with Myelofibrosis: A Proposed New Instrument the Myelofibrosis Symptom Assessment Form (MFSAF).
Authors: Ruben A. Mesa, Susan Schwager, Deepti Radia, Andrea Cheville, Kebede Hussein, Joyce Niblack, Animesh D. Pardanani, David P. Steensma, Mark R. Litzow, Candido E. Rivera, John Camoriano, Srdan Verstovsek, Jeffrey Sloan, Claire Harrison, Ayalew Tefferi
Journal: Blood (2008)
Child refugees: the right to compassion
Authors: Sebastian Taylor, Geoff Debelle, Neena Modi
Journal: BMJ (2016)

The UK must do more to meet its moral and legal obligations to migrant children

The United Nations refugee agency estimated that the number of people forcibly displaced around the world topped 60 million in 2015.1 In the same year, 270 000 asylum seeking children arrived in southern Europe. The phenomenon of globally mobile populations is not short term; it is the “new normal,” and the UK—like other high income countries—might have been expected to have had a clear, predefined response.

Ninety five per cent of the refugees who have recently arrived in Europe came by sea; a quarter of them were minors.2 In 2015, a third of the refugees who drowned in the Aegean were children.3 Sadly, arrival on the European mainland does not bring safety. At the time of writing, the UK has managed to take in only about 300 children from …
C-myc Abnormalities in Non-Hodgkins Lymphoma - A Retrospective Review of Cytogenetic Patterns and Clinical Impact of c-myc Abnormalities by FISH Testing.
Authors: Vishal Kukreti, Sabina Vohra, Kathy Chun, Denis Bailey, Bruce J. Patterson, Scott Boerner, William R. Geddie, Michael Crump
Journal: Blood (2005)
Patients (Pts) with Ph+ Chronic Myeloid Leukemia In Chronic Phase (CML-CP) with a Suboptimal Molecular Response to Imatinib (IM) Can Achieve Deeper Responses When Switched to Nilotinib
Authors: Carole Miller, Sikander Ailawadhi, Anand P. Jillella, Jerald P. Radich, Daniel J DeAngelo, Stuart L Goldberg, Denise Williams, Felice P. Lin, Luke Paul Akard
Journal: Blood (2010)
Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation.
Authors: Joerg Hasford, Michael Lauseker, Insa Gathmann, Markus Pfirrmann, Richard A. Larson, François Guilhot, Stephen G O’Brien, Brian J. Druker, Ruediger Hehlmann, Andreas Hochhaus
Journal: Blood (2008)
Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity
Authors: S. I. Ou, A. Ziogas, J. A. Zell
Journal: Journal of Clinical Oncology (2008)

8004 Background: Never-smokers with non-small cell lung cancer (NSCLC) have unique epidemiologic features and survival outcome. Methods: This retrospective population-based study of never-smokers with NSCLC involves analysis of NSCLC cases from the Cancer Surveillance Programs of three Southern California counties from 1991 to 2005. Results: 25,204 NSCLC patients with known smoking status were analyzed. 2240 patients (8.9%) were never-smokers. More females, more adenocarcinoma, approximately 3-fold more bronchioloalveolar carcinoma (BAC), and more distant disease were found among never-smokers. Median age of presentation was higher for never-smokers (vs. smokers; 71 vs. 69 years; P < .0001). Overall survival (OS) (P < .0001) and lung cancer-specific survival (LCSS) (P < .0001) in never-smokers were significantly improved over smokers. Never-smokers with distant disease (8 months OS improvement) benefited more from chemotherapy than smokers (6 months OS improvement). By multivariate analysis smoking status remained a significant poor prognostic factor for OS (vs. never-smokers, HR = 1.140, 95% CI: 1.080–1.203) and LCSS (vs. never-smoker, HR = 1.159, 95% CI: 1.090–1.233). Asian ethnicity was a favorable prognostic factor for OS among smokers (vs. Caucasian, HR = 0.847, 95% CI: 0.794–0.904) and never-smokers (vs. Caucasian, HR = 0.861, 95% CI: 0.750–0.988). Conclusions: Ever-smoking status is a poor prognostic factor in NSCLC. Among female NSCLC patients, Asians (45.6%) has the highest percentage of never-smokers followed by Hispanics (25.0%), Caucasians (12.6%) and African-Americans (10.8%). Asian ethnicity is a favorable prognostic factor among smokers and never-smokers. No significant financial relationships to disclose.
Species-Dependent Variability of ADAMTS-13 Mediated Proteolysis of Human Recombinant von Willebrand Factor.
Authors: Katalin Varadi, Hanspeter Rottensteiner, Peter L. Turecek, Jutta Schreiner, Herbert Gritsch, Bernhard Baumgartner, Eva-Maria Muchitsch, Hartmut Ehrlich, Hans Peter Schwarz
Journal: Blood (2007)
90-Yttrium Ibritumomab Tiuxetan (Zevalin) and BEAM Chemotherapy (Z-BEAM) Vs BEAM for Autologous Stem Cell Transplantation in Lymphoma: Toxicity and Long Term Outcome From a Retrospective Multicentric Study of 123 Patients.
Authors: Louis Terriou, Hanane Gasmi, Salomon Manier, Isabelle Plantier, Marc Wetterwald, Pauline lionne-Huyghe, Daniela Robu, Sabine Tricot, Ibrahim Yakoub-Agha, Nicolas Simon, Pascal Odou, Franck Morschhauser
Journal: Blood (2012)
Oncogenic Transcription Factor Evi1 Regulates Hematopoietic Stem Cell Proliferation through GATA-2 Expression.
Authors: Hiromi Yuasa, Yuichi Oike, Atsushi Iwama, Daisuke Sugiyama, Ichiro Nishikata, Archibald S. Perkins, Micheal L. Mucenski, Kazuhiro Morishita, Toshio Suda
Journal: Blood (2004)